马来酸依那普利叶酸片降压和/或降Hcy的时间疗效及甲基四氢叶酸还原酶C677T基因多态性对疗效的修饰作用
2018-03-08邹小秋谭启林何梅珍吴湖兰甘斌修刘青平房勇
邹小秋+谭启林+何梅珍+吴湖兰+甘斌修+刘青平+房勇
【摘要】 目的:对马来酸依那普利叶酸片降压和/或降同型半胱氨酸(Homocysteine,Hcy)的时间疗效及甲基四氢叶酸还原酶(Methylene tetrahydrofolate reductase,MTHFR)C677T基因多态性对疗效的修饰作用进行分析和探讨。方法:选取2013年1月-2016年12月本院收治的200例高同型半胱氨酸高血压患者,依据随机数字表分为观察组和对照组,每组100例。两组患者均接受相同的常规治疗,在此基础上再给予观察组患者马来酸依那普利叶酸片,分析马来酸依那普利叶酸片降压和/或降Hcy的时间疗效并从基因角度探讨甲基四氢叶酸还原酶C677T基因多态性对疗效的修饰作用。结果:观察组患者治疗后的血浆Hcy水平低于对照组,差异有统计学意义(P<0.05);观察组中,TT型患者治疗前血浆Hcy水平以及治疗后的血浆Hcy下降水平均高于CC、CT型患者,差异均有统计学意义(P<0.05)。结论:马来酸依那普利叶酸片治疗高同型半胱氨酸高血压有着较好的降Hcy疗效;在MTHFR C677T基因中,其对TT型患者的疗效最显著。
【關键词】 马来酸依那普利叶酸片; 同型半胱氨酸; 甲基四氢叶酸还原酶C677T; 基因多态性
【Abstract】 Objective:To analyze and discuss lower blood pressure and/or homocysteine(Hcy) effects of Enalapril Maleate Tablets and modification efficacy of methyl tetrahydrofolate reductase C677T polymorphism.Method:From January 2013 to December 2016,200 patients with Hcy hypertension treated in our hospital were selected and divided into the observation group and the control group according to the random number table method,100 patients in each group.Both of two groups patients were given conventional therapy,on the basis of which the patients in the observation group were treated with Enalapril Maleate Tablets.Lower blood pressure and/or Hcy effects of Enalapril Maleate Tablets and modification efficacy of methyl tetrahydrofolate reductase C677T polymorphism were analyzed.Result:After the treatment,plasma Hcy level of the observation group were lower than that of the control group,the difference was statistic significant(P<0.05).Plasma Hcy levels before treatment and plasma Hcy reduce levels after treatment of TT patients were higher than those of CC and CT patients in the observation group,the differences were statistically significant(P<0.05).Conclusion:Enalapril Maleate Tablets in the treatment of high Hcy hypertension with has a good effect of reduce Hcy,which has the most significant effect for TT patients among MTHFR C677T gene.
【Key words】 Enalapril Maleate Tablets; Homocysteine; Methyl tetrahydrofolate reductase C677T; Gene polymorphism
First-authors address:Yichun Second Peoples Hospital,Yichun 336000,China
doi:10.3969/j.issn.1674-4985.2017.23.016
伴有血浆同型半胱氨酸(Homocysteine,Hcy)增高的原发性高血压又可称为H型高血压,有研究证实,原发性高血压所导致的心脑血管事件与人体Hcy水平的升高存在协同作用,即高Hcy水平可增加患者高血压发生风险,反之高血压又可加剧人体内Hcy水平[1-3]。基于此选取部分于本院接受治疗的高同型半胱氨酸高血压患者为研究对象,分析探讨马来酸依那普利叶酸片的临床疗效及MTHFR C677T基因多态性对疗效的修饰作用。现报道如下。
1 资料与方法
1.1 一般资料 采用随机平行对照方法进行试验设计,基于已知MTHFR C677T基因型按照1∶1∶1的比例选择2013年1月-2016年12月于本院治疗的200例高血压患者,纳入标准血压符合WHO/ISH(2005年)中关于高血压诊断的相关标准,(1)收缩压>140 mm Hg和/或舒张压>90 mm Hg,空腹Hcy水平>15 μmol/L;(2)血常规、心电图、肝肾功能等检查未发现严重疾病;(3)自愿参加本次研究并主动签署知情同意书。排除标准:(1)哺乳期、妊娠期妇女以及对相关药物过敏的患者;(2)患有严重的精神类疾病无法配合研究的患者;(3)患有恶性肿瘤并接受过大型手术治疗的患者,正在接受降脂、维生素B、叶酸等药物治疗患者[4]。100例患者采用随机数字表法分为观察组和对照组,每组100例,两组患者一般资料比较,差异均无统计学意义(P>0.05),具有可比性,见表1。本研究经医院伦理委员会批准。endprint